Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Kill Curves versus MIC
暂无分享,去创建一个
Hartmut Derendorf | H. Derendorf | Markus Mueller | Amparo de la Peña | Markus Mueller | A. de la Peña
[1] A. Hoffman,et al. Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. , 1999, Critical reviews in therapeutic drug carrier systems.
[2] J. Rotschafer,et al. An in Vitro Pharmacodynamic Model to Simulate Antibiotic Behavior of Acute Otitis Media with Effusion , 1992, Pharmaceutical Research.
[3] O. Cars,et al. In Vitro Studies of Pharmacodynamic Properties of Vancomycin against Staphylococcus aureus andStaphylococcus epidermidis , 1998, Antimicrobial Agents and Chemotherapy.
[4] G. Drusano. Human pharmacodynamics of beta-lactams, aminoglycosides and their combination. , 1990, Scandinavian journal of infectious diseases. Supplementum.
[5] D. Reeves. Advantages and disadvantages of an in-vitro model with two compartments connected by a dialyser: results of experiments with ciprofloxacin. , 1985, The Journal of antimicrobial chemotherapy.
[6] J. Turnidge. The Pharmacodynamics of β-Lactams , 1998 .
[7] H. Derendorf. Pharmacokinetic evaluation of beta-lactam antibiotics. , 1989, The Journal of antimicrobial chemotherapy.
[8] J. Blaser,et al. Once-daily dosing of aminoglycosides , 1995, European Journal of Clinical Microbiology and Infectious Diseases.
[9] C. Wa. Choosing an antibiotic on the basis of pharmacodynamics. , 1998 .
[10] E. R. Garrett,et al. KINETICS AND MECHANISMS OF ACTION OF ANTIBIOTICS ON MICROORGANISMS. I. REPRODUCIBILITY OF ESCHERICHIA COLI GROWTH CURVES AND DEPENDENCE UPON TETRACYCLINE CONCENTRATION. , 1964, Journal of pharmaceutical sciences.
[11] Garrett Er. Kinetics of antimicrobial action. , 1978, Scandinavian journal of infectious diseases. Supplementum.
[12] J. Blaser,et al. Use of an in-vitro kinetic model to study antibiotic combinations. , 1985, The Journal of antimicrobial chemotherapy.
[13] M. Sachdeva,et al. Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. , 1990, Journal of Infectious Diseases.
[14] D. Nicolau,et al. Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections , 1994, Antimicrobial Agents and Chemotherapy.
[15] H. Derendorf. Pharmacokinetic evaluation of -lactam antibiotics , 1989 .
[16] Jerome J. Schentag,et al. Achieving an Optimal Outcome in the Treatment of Infections , 1999, Clinical pharmacokinetics.
[17] J. Turnidge,et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. , 1988, The Journal of infectious diseases.
[18] R. Hancock,et al. Novel method for measurement of outer membrane permeability to new beta-lactams in intact Enterobacter cloacae cells , 1991, Antimicrobial Agents and Chemotherapy.
[19] A. Smith,et al. Correction for bacterial loss in in vitro dilution models , 1987, Antimicrobial Agents and Chemotherapy.
[20] H. Chambers,et al. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis , 1990, Antimicrobial Agents and Chemotherapy.
[21] Jerome J. Schentag,et al. Potential Role of Pharmacokinetics, Pharmacodynamics, and Computerized Databases in Controlling Bacterial Resistance , 2000, Infection Control & Hospital Epidemiology.
[22] E. R. Garrett,et al. Kinetics and mechanisms of action of antibiotics on microorganisms. V. Chloramphenicol and tetracycline affected Escherichia coli generation rates. , 1966, Journal of pharmaceutical sciences.
[23] Jerome J. Schentag,et al. Integration of pharmacokinetics and pharmacodynamics of methicillin in curative treatment of experimental endocarditis. , 1984, The Journal of antimicrobial chemotherapy.
[24] A. Medeiros,et al. Net Effect of Inoculum Size on Antimicrobial Action of Ampicillin-Sulbactam: Studies Using an In Vitro Dynamic Model , 2006, Antimicrobial Agents and Chemotherapy.
[25] M. Laurentie,et al. Pharmacokinetic-pharmacodynamic model for spiramycin in staphylococcal mastitis. , 1996, Journal of veterinary pharmacology and therapeutics.
[26] H. Derendorf,et al. Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. , 1997, International journal of clinical pharmacology and therapeutics.
[27] I. Odenholt-Tornqvist. Pharmacodynamics of beta-lactam antibiotics. Studies on the paradoxical and postantibiotic effects in vitro and in an animal model. , 1988, Scandinavian journal of infectious diseases. Supplementum.
[28] Jianguo Zhi,et al. Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due toPseudomonas aeruginosa , 1988, Journal of Pharmacokinetics and Biopharmaceutics.
[29] T. Eden. Long-standing otitis media with effusion--a convenient model for the study of antibiotic penetration to respiratory tract secretions. , 1985, Scandinavian Journal of Infectious Diseases. Supplementum.
[30] Hartmut Derendorf,et al. Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives , 1999, Pharmaceutical Research.
[31] K. Fuursted,et al. Pharmacodynamics of Glycopeptides in the Mouse Peritonitis Model of Streptococcus pneumoniae orStaphylococcus aureus Infection , 2000, Antimicrobial Agents and Chemotherapy.
[32] Jerome J. Schentag,et al. Pharmacodynamic Modeling of Risk Factors for Ciprofloxacin Resistance in Pseudomonas aeruginosa , 2000, Infection Control & Hospital Epidemiology.
[33] J. Guggenbichler,et al. Kill kinetics of bacteria under fluctuating concentrations of various antibiotics. II. Description of experiments. , 1986, Chemotherapy.
[34] J. Mordenti,et al. Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model. , 1985, Journal of Antimicrobial Chemotherapy.
[35] Mary Jane Ferraro,et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .
[36] Claude Carbón,et al. Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant , 1992, Antimicrobial Agents and Chemotherapy.
[37] E. R. Garrett,et al. Kinetics and mechanisms of drug action on microorganisms. XIV. The action of fluorouracil, other uracils and derived nucleosides on the microbial kinetics of Escherichia coli. , 1972, Chemotherapy.
[38] E. R. Garrett,et al. Kinetics and Mechanisms of Drug Action on Microorganisms , 1969 .
[39] T. D. Costa,et al. AUIC — A General Target for the Optimization of Dosing Regimens of Antibiotics? , 1996, The Annals of pharmacotherapy.
[40] L. Engstrand,et al. New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms , 1996, Antimicrobial agents and chemotherapy.
[41] Jerome J. Schentag,et al. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. , 2000, The Journal of antimicrobial chemotherapy.
[42] L. Peterson,et al. Influence of protein binding on therapeutic efficacy of cefoperazone , 1989, Antimicrobial Agents and Chemotherapy.
[43] S. Keil,et al. Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models , 1995, Antimicrobial agents and chemotherapy.
[44] Jerome J. Schentag,et al. Pharmacodynamic interactions of antibiotics alone and in combination. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[45] Jerome J. Schentag,et al. The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to Outcome , 1995, Clinical pharmacokinetics.
[46] W. Craig,et al. Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[47] Jerome J. Schentag. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. , 1999, Journal of chemotherapy.
[48] J. Aeschlimann,et al. Pharmacodynamic Analysis of the Activity of Quinupristin-Dalfopristin against Vancomycin-ResistantEnterococcus faecium with Differing MBCs via Time-Kill-Curve and Postantibiotic Effect Methods , 1998, Antimicrobial Agents and Chemotherapy.
[49] H. Derendorf,et al. Pharmacokinetic-Pharmacodynamic Modeling of the Antibiotic Effect of Piperacillin in Vitro , 2004, Pharmaceutical Research.
[50] E. R. Garrett. Kinetics of antimicrobial action. , 1978, Scandinavian journal of infectious diseases. Supplementum.
[51] D. Musher,et al. Vancomycin penetration into biofilm covering infected prostheses and effect on bacteria. , 1994, The Journal of infectious diseases.
[52] R. Vasilov,et al. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model. , 1999, The Journal of antimicrobial chemotherapy.
[53] Jerome J. Schentag,et al. Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy , 1998, Antimicrobial Agents and Chemotherapy.
[54] N. Frimodt-Møller,et al. Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins. , 1986, The Journal of infectious diseases.
[55] W. Craig. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. , 1995, Diagnostic microbiology and infectious disease.
[56] J. Blaser,et al. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model , 1985, Antimicrobial Agents and Chemotherapy.
[57] T. Vondracek,et al. Beta-Lactam Antibiotics: Is Continuous Infusion The Preferred Method of Administration? , 1995, The Annals of pharmacotherapy.
[58] A. Sánchez-Navarro,et al. Basis of Anti-Infective Therapy , 1999, Clinical pharmacokinetics.
[59] E. Bruck,et al. National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.
[60] O. Cars,et al. Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model , 1996, Antimicrobial agents and chemotherapy.
[61] R. Moore,et al. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. , 1987, The Journal of infectious diseases.
[62] C. Stratton,et al. Correlation of serum bactericidal activity with antimicrobial agent level and minimal bactericidal concentration. , 1982, The Journal of infectious diseases.
[63] B. Ledergerber,et al. Computer-controlled in-vitro simulation of multiple dosing regimens. , 1985, The Journal of antimicrobial chemotherapy.
[64] S. Palmer,et al. An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots. , 1997, The Journal of antimicrobial chemotherapy.
[65] G. Kaatz,et al. Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis , 1994, Antimicrobial Agents and Chemotherapy.
[66] J. Blaser,et al. In-vitro studies of antibiotic combinations with special emphasis on the evaluation of newly developed methods. , 1986, The Journal of antimicrobial chemotherapy.
[67] W. Craig. Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA , 1995, European Journal of Clinical Microbiology and Infectious Diseases.
[68] Jerome J. Schentag,et al. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar , 1994, Antimicrobial Agents and Chemotherapy.
[69] W. Craig. Choosing an antibiotic on the basis of pharmacodynamics. , 1998, Ear, nose, & throat journal.
[70] S. Palmer,et al. Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model , 1995, Antimicrobial agents and chemotherapy.
[71] Jerome J. Schentag. Pharmacokinetic and pharmacodynamic surrogate markers: studies with fluoroquinolones in patients. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[72] J. Blaser,et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance , 1987, Antimicrobial Agents and Chemotherapy.
[73] T. Bergan,et al. An in vitro model for monitoring bacterial responses to antibiotic agents under simulated in vivo conditions , 2005, Infection.
[74] M. Hammerschlag,et al. In Vitro Activities of Azithromycin and Ofloxacin againstChlamydia pneumoniae in a Continuous-Infection Model , 1999, Antimicrobial Agents and Chemotherapy.
[75] S. Zinner,et al. Prediction of the Effects of Inoculum Size on the Antimicrobial Action of Trovafloxacin and Ciprofloxacin againstStaphylococcus aureus and Escherichia coli in an In Vitro Dynamic Model , 1999, Antimicrobial Agents and Chemotherapy.
[76] J. Mordenti,et al. Effect of dose on pharmacokinetics and serum bactericidal activity of mezlocillin , 1987, Antimicrobial Agents and Chemotherapy.
[77] T. Bergan,et al. Effect of antibiotics eliminated by first order kinetics. , 1985, Journal of Antimicrobial Chemotherapy.
[78] W. Craig,et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. , 1989, The Journal of infectious diseases.
[79] R. van Furth,et al. Comparison of the antibacterial activity of azlocillin and ticarcillin in vitro and in irradiated neutropenic mice. , 1985, The Journal of antimicrobial chemotherapy.
[80] W. Craig,et al. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. , 1999, Infectious disease clinics of North America.
[81] A. Firsov,et al. Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model , 1990, Antimicrobial Agents and Chemotherapy.
[82] J. Turnidge. The pharmacodynamics of beta-lactams. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[83] J. Blaser,et al. Two compartment kinetic model with multiple artificial capillary units. , 1985, The Journal of antimicrobial chemotherapy.
[84] C. Colino,et al. A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin. , 2000, The Journal of antimicrobial chemotherapy.
[85] A. Firsov,et al. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model , 1997, Antimicrobial agents and chemotherapy.
[86] B. Guglielmo,et al. Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens , 1988, Antimicrobial Agents and Chemotherapy.
[87] G. Eliopoulos,et al. Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats , 1987, Antimicrobial Agents and Chemotherapy.
[88] P. Francioli,et al. Successful prophylaxis of experimental streptococcal endocarditis with single doses of sublethal concentrations of penicillin. , 1985, The Journal of antimicrobial chemotherapy.
[89] W J Jusko,et al. Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. , 1971, Journal of pharmaceutical sciences.
[90] H Derendorf,et al. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. , 1997, International journal of clinical pharmacology and therapeutics.
[91] J. Waitz. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .
[92] E. H. White,et al. An In Vitro Tissue Culture Bilayer Model To Examine Early Events in Mycobacterium tuberculosisInfection , 1999, Infection and Immunity.
[93] T. Drake,et al. Effects of sub-bactericidal concentrations of antibiotics in experimental models of endocarditis. , 1985, Journal of Antimicrobial Chemotherapy.
[94] T. Bergan,et al. Bacterial kill rates of amoxycillin and ampicillin at exponentially diminishing concentrations simulating in vivo conditions , 2005, Infection.
[95] H. Eichler,et al. Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers , 2000, Clinical pharmacology and therapeutics.
[96] W. Craig,et al. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. , 1991, The Journal of antimicrobial chemotherapy.
[97] Jerome J. Schentag,et al. Mathematical Examination of Dual Individualization Principles (I): Relationships between AUC above MIC and Area under the Inhibitory Curve for Cefmenoxime, Ciprofloxacin, and Tobramycin , 1991, DICP : the annals of pharmacotherapy.
[98] E. R. Garrett,et al. Kinetics and mechanisms of drug action on microorganisms. XVII. Bactericidal effects of penicillin, kanamycin, and rifampin with and without organism pretreatment with bacteriostatic chloramphenicol, tetracycline, and novobiocin. , 1973, Journal of pharmaceutical sciences.
[99] J. Blaser,et al. Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model , 1985, Antimicrobial Agents and Chemotherapy.
[100] M. Nishida,et al. New in vitro kinetic model for evaluating bactericidal efficacy of antibiotics , 1980, Antimicrobial Agents and Chemotherapy.
[101] Carl Peck,et al. An Evaluation of the Integration of Pharmacokinetic and Pharmacodynamic Principles in Clinical Drug Development , 1997, Clinical pharmacokinetics.
[102] H. Eagle,et al. THE RATE OF BACTERICIDAL ACTION OF PENICILLIN IN VITRO AS A FUNCTION OF ITS CONCENTRATION, AND ITS PARADOXICALLY REDUCED ACTIVITY AT HIGH CONCENTRATIONS AGAINST CERTAIN ORGANISMS , 1948, The Journal of experimental medicine.
[103] C. Nightingale. Pharmacokinetics of the oral cephalosporins in adults. , 1980, The Journal of international medical research.
[104] W. Craig,et al. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. , 1996, The Pediatric infectious disease journal.
[105] A. Sanfilippo,et al. An experimental model for the study of the antibacterial activity of the sulfonamides. , 1968, Chemotherapia.
[106] G. Drusano. Infection in the intensive care unit: beta-lactamase-mediated resistance among Enterobacteriaceae and optimal antimicrobial dosing. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[107] M. Sachdeva,et al. Binding Affinity for Penicillin-Binding Protein 2a Correlates with In Activity of β-Lactan Antibiotics against Methicillin-Resistant Staphylococcus aureus , 1990 .
[108] C. Edmiston,et al. Pharmacodynamics of antimicrobial therapy in surgery. , 1996, American journal of surgery.
[109] F. O'grady,et al. An in vitro model of the urinary bladder. , 1978, The Journal of antimicrobial chemotherapy.
[110] John M. Blatt,et al. Description of the Model , 1988 .
[111] S. Zinner,et al. Inter- and Intraquinolone Predictors of Antimicrobial Effect in an In Vitro Dynamic Model: New Insight into a Widely Used Concept , 1998, Antimicrobial Agents and Chemotherapy.
[112] W. Craig,et al. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[113] Schentag Jj,et al. Potential impact of quantitative susceptibility tests on the design of aminoglycoside dosing regimens. , 1987 .
[114] J. Guggenbichler,et al. Kill kinetics of bacteria under fluctuating concentrations of various antibiotics. I. Description of the model. , 1986, Chemotherapy.
[115] W. Craig. Antimicrobial resistance issues of the future. , 1996, Diagnostic microbiology and infectious disease.
[116] H. Mattie,et al. Influence of aminopenicillins on bacterial growth kinetics in vitro in comparison with the antibacterial effect in vivo , 2005, Infection.
[117] V. Tamassia,et al. New In Vitro Model to Study the Effect of Antibiotic Concentration and Rate of Elimination on Antibacterial Activity , 1978, Antimicrobial Agents and Chemotherapy.
[118] S. Zinner,et al. A New Approach to In Vitro Comparisons of Antibiotics in Dynamic Models: Equivalent Area under the Curve/MIC Breakpoints and Equiefficient Doses of Trovafloxacin and Ciprofloxacin against Bacteria of Similar Susceptibilities , 1998, Antimicrobial Agents and Chemotherapy.
[119] X. Barbaut,et al. Comparisons between Antimicrobial Pharmacodynamic Indices and Bacterial Killing as Described by Using the Zhi Model , 1998, Antimicrobial Agents and Chemotherapy.
[120] A. Widmer,et al. In vivo verification of in vitro model of antibiotic treatment of device-related infection , 1995, Antimicrobial agents and chemotherapy.